The following table summarizes the stock option activity for the six months ended June 30, 2026:


	Shares (in thousands)			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)
Outstanding at December 31, 2025		28,705		$	2.98		7.64
Granted		366		$	0.99
Exercised		—		$	—
Expired and forfeited		(808	)	$	7.30
Outstanding at June 30, 2026		28,263		$	2.83		7.24

We estimated the fair value of each option grant on the grant date using the Black-Scholes option pricing model. The following are the weighted-average assumptions:


	For the Six Months Ended June 30,
	2026			2025
Risk-free interest rate		3.9	%		4.3	%
Dividend yield		0.0	%		0.0	%
Volatility		79.9	%		80.1	%
Expected life (years)	6 to 10			6 to 10

The following table summarizes the restricted stock unit activity ("RSUs") for the six months ended June 30, 2026:


	Shares (in thousands)			Weighted-Average Grant Date Fair Value
Outstanding at December 31, 2025		3,799		$	1.91
Granted		8,051		$	1.31
Released		(1,084	)	$	1.73
Expired and forfeited		(187	)	$	1.51
Outstanding at June 30, 2026		10,579		$	1.49

The fair value of RSUs is estimated based on the closing market price of our common stock on the date of the grant. RSUs generally vest quarterly over a four-year period.

We estimated the fair value of each purchase right granted under our 1997 Employee Stock Purchase Plan, as amended, at the beginning of each new offering period using the Black-Scholes option pricing model. The following are the weighted average assumptions:


	For the Six Months Ended June 30,
	2026			2025
Risk-free interest rate		3.8	%		4.2	%
Dividend yield		0.0	%		0.0	%
Volatility		67.7	%		79.1	%
Expected life (months)		6			6

The following table summarizes stock-based compensation expense related to stock-based payment awards granted pursuant to all of our equity compensation arrangements (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Research and development	$	278	$	276	$	532	$	521
General and administrative		1,979		1,825		3,833		3,396
Sales and marketing		921		696		1,789		1,391
Total stock-based compensation expense	$	3,178	$	2,797	$	6,154	$	5,308

As of June 30, 2026, there was $26.2 million of total unrecognized compensation cost related to non-vested, stock-based payment awards granted under all of our equity compensation plans and all non-plan option grants. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. We expect to recognize this compensation cost over a weighted-average period of two years.